Drugs / JinFuKang
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02603003 | Jun 2015 → Sep 2019 | non-small cell lung carcinoma | Shanghai University of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00260026 | Nov 2004 → Jan 2007 | non-small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02777788 | Sep 2014 → Dec 2019 | cancer | Shanghai University of Traditional Chinese Medicine | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JinFuKang | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02777788 ↗ |
| Known as | JinFuKang oral liquid | “JinFuKang oral liquid” NCT02777788 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Jin Fu Kang is a herbal medicine specially developed in China for the treatment of lung cancer.” NCT00260026 ↗ |
| Route | Oral | “po.tid.30ml” NCT02603003 ↗ |